Introduction
Major neurologic manifestations related principally to infections, drug toxicity, metabolic abnormality and Epstein-Barr virus (EBV) related lymphoma occur in approximately 25% of fully ablative allogeneic hematopoietic stem cell transplants (allo-HSCT). Clinically significant neurologic manifestations in allo-HSCT are associated with graft-versus-host disease (GVHD) and increased mortality. 1 GVHD is a systemic syndrome mediated by T cells of donor origin and principally targeting skin, gut and liver. Involvement of other organ systems is described; however, confounding factors including infections, drugs and autoimmune manifestations can make diagnosis challenging. Of the 10 patients with possible central nervous system (CNS)-GVHD described in the English literature, [2] [3] [4] [5] [6] [7] [8] [9] [10] histologic interpretation is available in only five cases; 2, 3, 5, 8 and ante-mortem histologic diagnosis was established in only one. 8 In this report we describe two cases of possible CNS-GVHD where the diagnosis was accompanied by extensive immunophenotype and chimeric studies.
Case report 1
A 44-year old female underwent matched related allogeneic transplantation from her brother in 1998 for refractory T-cell lymphoma composed of predominantly large cells. Transplant conditioning and GVHD prophylaxis consisted of cyclophosphamide plus total body irradiation (CY/TBI) and tacrolimus plus short methotrexate, respectively. Rapid and sustained engraftment occurred within 2 weeks with 100% donor chimerism. Post-transplant surveillance was negative for cytomegalovirus (CMV). She developed grade I GVHD (skin rash) that resolved quickly without active therapy and she achieved complete remission. Her immunosuppressants were tapered within 6 months and she had limited chronic GVHD (cGVHD) in form of thickening of skin. Approximately 18 months following allogeneic transplant, she developed a subacute onset of right hemiparesis and seizure. A magnetic resonance imaging (MRI) revealed an infiltrating lesion in the white matter of her left fronto-parietal lobe with minimal enhancement and no mass effect. Cerebrospinal fluid (CSF) examination revealed no pleocytosis, protein elevation or oligoclonal band and was negative for bacterial, viral or fungal infections. A brain biopsy revealed perivascular inflammation, which was predominately located within the brain parenchyma ( Figure 1a) . The inflammatory cells were mainly small mature T-lymphocytes with a helper T-cell immunophenotype expressing CD3 (Figure 1b ) and CD4 ( Figure 1c ) but not CD8, TIA-1 (Figure 1d ) or CD56 (Dako automated immunostainer, Carpentaria, CA, USA). Fluorescent in situ hybridization analysis for XY chromosome confirmed that all the lymphocytes examined are of donor origin. This finding and the benign appearance of the T-lymphocytes argue against the possibility of CNS relapse of the original T-cell lymphoma. Immunohistochemical stains were negative for EBV and JC virus as well as toxoplasmosis. Compete workup for collagen vascular disease, autoimmune disease and infectious causes includ-ing CMV, toxoplasma, cryptococcus and herpes simplex virus-6 (HSV-6) were negative.
Following exclusion of an infectious process, she underwent empiric therapy with methyl prednisone (500 mg every 12 h Â 5 days) resulting in progressive clinical improvement in her neurologic deficit leading to 95% functional improvement. A repeat MRI examination however revealed persistence of the brain lesion. A repeat course of methyl prednisone 1 year after the initial treatment for persistent CNS lesion resulted in near complete resolution of the lesion. She is free of any neurological symptoms and in complete remission for her lymphoma for 6 years and 8 years, respectively.
Case report 2
A 58-year old Caucasian female was diagnosed with Philadelphia positive B-cell acute lymphoblastic leukemia with CNS disease. She achieved a complete hematologic and molecular remission and CNS sterilization with repetitive intrathecal therapy, eight cycles of hyper CVAD and imantinib. She then received a 5/6 histocompatibility leukocyte antigen mismatched unrelated donor peripheral blood stem cell transplant (conditioning with TBI 450 cGY, Fludarabine 30 mg/m 2 Â 4, Alemtuzumab 10 mg Â 3 and anti-CD-45 Â 4 days).
11 Engraftment occurred on day 12 with full donor chimerism and she developed grade II acute GVHD (aGVHD) and later limited cGVHD involving skin and gut. On day 178 after alloHSCT, she presented with encephalopathy and seizure. An MRI examination revealed, patchy areas of increased intensity in pontine white matter, caudate nuclei, the putamina, bilateral cerebral and cerebellar white matter. CMV antigen was negative (CMV and polymerase chain reaction (PCR) had 55 copies/ml); viral studies were negative for HSV-6, HSV and EBV. CSF studies revealed 1-lymphocyte/mm 3 , protein elevation (62 mg/dl), and normal glucose and lactate dehydrogenase 
Discussion
CNS-GVHD remains a controversial entity in hematopoietic transplantation. Animal studies 12, 13 based on the expression of myosin heavy chain molecules in the CNS support the possibility of brain being a target for the development of GVHD. CNS-GVHD has also been reported in autopsy reports. 2, 3, 14 However, diagnostic substantiation of CNS-GVHD is difficult even in the autopsy setting. The very first report that described CNS-GVHD in 1988 15 based on focal lymphohistiocytic aggregates was later found to be EBV related lymphoproliferative disorder as delineated by positive EBER 10 years later. 16 Among the reported ante-mortem diagnosis of possible CNS-GVHD, a few had histologic corroboration. Table 1 illustrates salient features of the reported cases.
The diagnosis of CNS-GVHD in these previous reports (Table 1 ) and in our patients remain tentative and cannot be definitively established, as this entity is particularly difficult to prove. However, when relapse of CNS neoplastic process, opportunistic infections as well as EBV related post-transplant lymphoproliferative disorders (PTLD) 17, 18 among other diagnoses are excluded by means of thorough studies, the possibility of CNS-GVHD may be entertained. However, several questions surround this issue. Is CNS-GVHD a separate entity? If yes, can a firm diagnosis of CNS-GVHD be established convincingly? It is particularly important to exclude CNS-PTLD as similar to CNS-GVHD, it may present with perivascular lymphocytic infiltrates. However, most cases of CNS-PTLD are of B-cell phenotype and are associated with EBV infection. 17, 18 The accurate distinction of the two entities is critical as clinical management is distinctly different.
We agree with others 4-10 that CNS-GVHD may be considered only if there is no evidence of other diseases with overlapping features, radiographic characteristics of CNS involvement, response to immunosuppressive therapy and adequate documentation of perivascular T-cell infiltrate by histological and immunophenotypic evaluation. The presence of donor T cells in the brain biopsy specimen, although supportive of the diagnosis, should be interpreted cautiously and cannot be used as the sole evidence establishing the diagnosis of CNS-GVHD. The entire host lymphoid system is that of donor origin after stem cell transplantation and donor T cells are the only cells available for recruitment.
CNS-GVHD may present with a variety of clinical manifestations often associated with systemic GVHD. Histologically, two distinct pattern of brain involvement is described: one with vasculitis presenting with CNS angittis 5, 8 and the second with focal lymphocytic encephalitis and microglia activation. 2, 3 The leptomeningeal involvement as seen in our patient (case 2) has not been described previously.
In our cases, negative evaluation for multiple sclerosis and infectious processes including EBV, presence of systemic GVHD and extensive perivascular CD3 þ cell infiltration support the diagnosis of CNS-GVHD. Both patients were not on cyclosporine/tacrolimus at the time of development of CNS manifestations and had no evidence of microangiopathy. The finding of lymphocyte populations composed of different subsets in our patients (one case with cytotoxic T cells phenotype and the other with helper T-cell phenotype) of T cells is of interest and may represent different stages of CNS-GVHD in these two cases. Of note, in systemic GVHD CD4 infiltration may predominate in some cases and CD8 in other cases. Usually the CD4 appears earlier and is followed by CD8 but it also depends on the T-cell composition infused and in experimental situations both CD4 and CD8 can behave in a cytotoxic fashion or mobilize cytokines. Nonspecific MRI and CSF findings call for a high index of suspicion, pathologic verification and exclusion of any infectious process.
Continued reporting and working-up of similar cases will help to further delineate if CNS-GVHD represents a distinct entity and its clinical significance. At present, from the cases presented here and reported in the literature, CNS-GVHD is a diagnostic consideration in patients presenting an inflammatory CNS disease with predominance of T cells in allotransplant recipients that is noninfectious, non-neoplastic and cannot be attributed to known neurologic disorders.
